Participate in a Study
hello world!
Direct-to-Patient Site

Access 100% of your target population with the industry's only FDA-Inspected Direct-to-Patient Site

By bringing clinical research to the patients’ home with high quality care, and the detailed execution, delivery, and data collection you expect from your best sites.

The First & Only
FDA-Inspected Direct-to-Patient Site

Four Phase 3 Trials Inspected:

  • No Action Indicated (NAI) classification
  • No objectionable conditions noted
  • No Form 483 issued
  • No recommendations

Clinical Research Has a Patient Access Problem

Traditional brick-and-mortar research sites reach fewer than 10% of eligible clinical trial patients, leaving over 90% outside their catchment areas and often requiring long-distance travel to participate.

The Site That Visits The Patient

Science 37’s Direct-to-Patient Site enables sponsors to reach 100% of their target patient population  by conducting study visits in patients’ homes.

Direct-to-Patient Logistics

50-State Medical Licensure
Single 1572 and IRB Submission
IMP Shipment 
Kit and Study Supplies
Research Nurse Coordination 
Investigator Oversight
With 50-state licensure, our medical teams manage studies nationwide, ensuring broad patient access. This nationwide capability facilitates seamless enrollment regardless of the participant’s location. 
We simplify the approval process by consolidating regulatory requirements into a single 1572 and IRB submission. This streamlined approach reduces complexity, speeding up trial start-up and accelerating the path to First Patient In (FPI).
The Investigational Medicinal Product (IMP) is shipped from our central pharmacy partner directly to the patient’s home 1–2 days before the scheduled dosing visit. Our research-grade nurses ensure full chain of custody is maintained throughout the process.
Lab kits and study visit supplies are shipped from our headquarters directly to the participant’s home 1–2 weeks before the scheduled visit. Our research-grade nurses verify delivery upon arrival.
Our nationwide team of in-house research-grade nurses conducts study visits in patients’ homes. For each visit, the nearest qualified nurse is identified, and our central scheduling team manages all coordination.
Our investigators ensure participant safety and compliance through remote monitoring, in-home nurse visits, and real-time data access, mirroring traditional site investigators in a direct-to-patient model.

Feasibility

  • High Prevalence Chronic Diseases
  • Phase 2, 3, and 4 Interventional
  • Long-Term Follow-Up
  • Rare Diseases
  • Observational

Trusted for Over 10 Years in Direct-to-Patient Clinical Trial Delivery

185+ Clinical Trials

Supported across a wide range of study types and populations.

13,000+ In-Home Visits Nationwide

Delivering both standard and complex clinical assessments directly to participants across the U.S.

Therapeutic Experience

Atrial Fibrillation (AFib)
Pediatric Hypertension
Pulmonary Arterial Hypertension
Uncontrolled Hypertension and Suppressed Plasma Renin Activity
Vascular Ehlers-Danlos Syndrome (vEDS)

Acne Vulgaris
Basal Cell Carcinoma
Chronic Spontaneous Urticaria
Face & Neck Atopic Dermatitis
Herpes Labialis

Hidradenitis Suppurativa (HS)
Netherton Syndrome
Pemphigus Vulgaris
Psoriasis
Rosacea

Achondroplasia
Classic Congenital Adrenal Hyperplasia
Chronic Kidney Disease
Diabetic Kidney Disease
Distal Renal Tubular Acidosis

Nonalcoholic Fatty Liver Disease (NAFLD)
Phenylketonuria (PKU)
Prader-Willi Syndrome (PWS)
Severe Hypertriglyceridemia
T1D, T2D, and T3D Obesity

Bacterial Infections
C. Difficile Infection
Chronic Granulomatous Disease
COVID-19
Herpes Labialis

Human Immunodeficiency Virus (HIV)
Hypogammaglobulinemia
Immunocompromised Patients
Respiratory Viral Infections
Respiratory Syncytial Virus (RSV) Vaccine

Alzheimer's
Bipolar Depression
Cluster Headache
Epilepsy
GM2 Gangliosidosis
Idiopathic Hypersomnia
Major Depressive Disorder
Multiple Sclerosis

Narcolepsy
nOH in Multiple System Atrophy
Parkinson's Disease
Postpartum Depression
Rare Neurodevelopmental Disorder
Restless Leg Syndrome
Seizure

Age-Related Macular Degeneration
ALK+ non-NSCLC Tumors
B-cell Chronic Lymphocytic Leukemia
B-cell Mediated Autoimmune Disorders
Benign Hematologic Disorders
Breast Cancer
Chronic Myeloid Leukemia

Colorectal Cancer
Focal Segmental Glomerulosclerosis
Healthy Subjects for Cancer Screening
Lung Cancer
PBCAR-T Long-Term Follow-Up
Relapsed/Refractory Multiple Myeloma

Classical Homocystinuria (HCU)
Epidermolysis Bullosa
Fragile X Syndrome (FXS)
GM2 Gangliosidosis
Netherton Syndrome
Primary Biliary Cholangitis (PBC)
Primary Sclerosing Cholangitis (PSC)
Post-Allogeneic Hematopoietic Cell Transplant

Rare Neurodevelopmental Disorder
Severe Hemophilia A
Sickle Cell Disease
Spinal Muscular Atrophy
Vascular Ehlers-Danlos Syndrome (vEDS)
Von Willebrand Disease
22q11 Deletion Syndrome (Pediatric)

Chronic Obstructive Pulmonary Disease (COPD)
Chronic Rhinosinusitis w/ Nasal Polyps
Idiopathic Pulmonary Fibrosis
Pulmonary/Respiratory Complications in Patients with Neuromuscular Diseases (NMDs)
Refractory Chronic Cough

Connect with our team to explore how we can 
enhance patient access and enrollment for your trial.

Connect with our team to explore how we can enhance patient access and enrollment for your trial.

© 2025 Science 37 | All Rights Reserved